Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program

  • Corvus Pharmaceuticals Inc CRVS has shared data from the Phase 3 mupadolimab COVID-19 trial.
  • The data from 40 patients suggested improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. 
  • No drug-related adverse events were reported.
  • The Company said antiviral responses in the 2mg/kg cohort trended higher across all variants tested, including delta.
  • In July, Corvus discontinued the COVID-19 trial, which had planned to enroll approximately 1,000 patients due to positive trends exhibited by COVID-19 vaccines.
  • Related Content: Corvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology.
  • In the 2mg/kg cohort, 93.3% of patients were alive and free from respiratory failure, compared to 85.7% in the 1mg/kg cohort and 81.1% in the placebo. 
  • In addition, positive trends favoring mupadolimab treatment compared to placebo were seen for time to clinical improvement and hospital discharge.
  • Mupadolimab is currently being studied in a Phase 1b/2 study in patients with HPV+ oropharyngeal cancers and non-small cell lung cancers who have failed previous treatment with anti-PD-1 therapy and chemotherapy. 
  • Data from the study will be shared at the Society for Immunotherapy of Cancer (SITC) annual meeting in November.
  • Price Action: CRVS shares are down 9.38% at $7.73 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!